Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Vitamin D  COVID-19 treatment studies for Vitamin D  C19 studies: Vitamin D  Vitamin D   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 72% Improvement Relative Risk Secondary infection 23% c19early.org/d Batur et al. Vitamin D for COVID-19 ICU PATIENTS Sufficiency Are vitamin D levels associated with COVID-19 outcomes? Retrospective 194 patients in Turkey (March 2020 - June 2021) Lower mortality with higher vitamin D levels (p<0.000001) Batur et al., Diagnostics, doi:10.3390/diagnostics13010059 Favors vitamin D Favors control
Association between Vitamin D Status and Secondary Infections in Patients with Severe COVID-19 Admitted in the Intensive Care Unit of a Tertiary-Level Hospital in Turkey
Batur et al., Diagnostics, doi:10.3390/diagnostics13010059
Batur et al., Association between Vitamin D Status and Secondary Infections in Patients with Severe COVID-19 Admitted in the.., Diagnostics, doi:10.3390/diagnostics13010059
Dec 2022   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective 194 ICU patients and 30 non-COVID-19 patients in Turkey, showing significantly lower vitamin D levels in COVID-19 patients. There was significantly higher COVID-19 mortality with vitamin D deficiency, and significantly higher risk of secondary hospital infections.
Severe COVID-19 patients with vitamin D deficiency may have increased risks due to secondary infections. This study is excluded in the after exclusion results of meta analysis: unadjusted differences between groups.
risk of death, 71.9% lower, RR 0.28, p < 0.001, high D levels (≥20ng/mL) 17 of 76 (22.4%), low D levels (<20ng/mL) 94 of 118 (79.7%), NNT 1.7.
secondary infection, 23.3% lower, RR 0.77, p = 0.03, high D levels (≥20ng/mL) 40 of 76 (52.6%), low D levels (<20ng/mL) 81 of 118 (68.6%), NNT 6.2, growth in culture.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Batur et al., 26 Dec 2022, retrospective, Turkey, peer-reviewed, 2 authors, study period March 2020 - June 2021.
Contact: lbatur@biruni.edu.tr (corresponding author).
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperVitamin DAll
Abstract: diagnostics Article Association between Vitamin D Status and Secondary Infections in Patients with Severe COVID-19 Admitted in the Intensive Care Unit of a Tertiary-Level Hospital in Turkey Lutfiye Karcioglu Batur 1, * and Suna Koç 2 1 2 * Citation: Batur, L.K.; Koç, S. Association between Vitamin D Status and Secondary Infections in Patients with Severe COVID-19 Admitted in the Intensive Care Unit of a Tertiary-Level Hospital in Turkey. Diagnostics 2023, 13, 59. https:// doi.org/10.3390/diagnostics13010059 Academic Editor: Aw Tar-Choon Department of Molecular Biology and Genetics, Faculty of Engineering and Natural Sciences, Biruni University, Istanbul 34010, Turkey Department of Anesthesiology and Reanimation, Medical Faculty, Biruni University, Istanbul 34010, Turkey Correspondence: lbatur@biruni.edu.tr; Tel.: +90-444-82-76 (ext. 2133) Abstract: There are several studies showing that the vitamin D status can determine risk of COVID19 infections, severity and mortality from coronavirus disease 2019 (COVID-19). However, the association between vitamin D (25(OH)D) and secondary infections in the prognosis of COVID-19 patients has not been reported yet. The aim was to investigate whether the vitamin D status affects the rates of secondary infections in patients with severe COVID-19 hospitalized in the intensive care unit (ICU) of a tertiary-level hospital in Turkey. The data of 194 patients with diagnosis of severe COVID-19 who were admitted to the ICU from March 2020 to June 2021 and older than 18 years were evaluated in this retrospective study. The patients were divided into two groups according to total serum 25(OH)D level as normal group (≥20 ng/mL) and low group (<20 ng/mL). The 25(OH)D level was low in 118 (60.8%) and normal in 76 (39.2%) patients. The mean age of the low group was significantly higher than that of the normal group (67.02 ± 14.47 vs. 61.70 ± 14.38; p = 0.013). The systolic and diastolic blood pressure as well as the Glasgow coma scale score of the low group were significantly lower than that of the normal group (p = 0.004, 0.002 and 0.001, respectively). The intubation rate and APACHE (Acute Physiology and Chronic Health Evaluation) score of the low group was significantly higher than that of the normal group (p = 0.001). The platelets number and blood pH decreased, and the neutrophil/lymphocyte ratio, procalcitonin, lactate, urea, creatinine and lactate dehydrogenase concentrations increased significantly in the low group (p < 0.05). The mortality rate was 79.7% in the low group and 22.4% in the normal group (p < 0.001). Microbiological growth was observed in 68.6% of the normal group and 52.6% of the normal group (p = 0.025). The number of cultures with resistant bacteria was significantly higher in the low group (25.9%) than that in the normal group (17.5%) (p = 0.035). The severe COVID-19 patients hospitalized with vitamin D deficiency may have increased risks of poor prognosis and mortality due to secondary infections in the ICU. Keywords: vitamin D status; COVID-19; Intensive Care Unit; secondary infections Received: 25 October 2022 Revised: 16 December 2022 Accepted: 17 December 2022 Published: 26 December 2022 Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/).
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit